Astellas pain franchise awarded to Pegasus

Astellas Pharma Europe, part of one of the world's largest pharmaceutical companies, has awarded its pan-European pain management franchise to Pegasus.

Astellas: aims to raise awareness and understanding of peripheral neuropathic pain
Astellas: aims to raise awareness and understanding of peripheral neuropathic pain

The Sussex-based agency has been tasked with devising a programme to raise awareness and understanding of peripheral neuropathic pain (PNP).

The condition is caused by damaged nerves in the peripheral nervous system - the nervous system outside the brain and spinal chord - and often flares up following another condition, such as a stroke, spinal cord injury or multiple sclerosis.

Health professionals say the disease is particularly difficult to treat because every case is different.

A key plank of the brief will be to promote treatment patches, Qutenza, which contain the active ingredient capsaicin which relieves nerve pain in the skin by desensitising nerve receptors.

The manufacturer is part of a Tokyo-based global firm which employs 4,200 staff around the world, and is the holder of a five year European Uunion marketing authorisation awarded in 2009.

Mindy Dooa, corporate comms director at Astellas Pharma Europe said: 'The team presented some fresh, creative ideas and strong strategic insights, which was combined with a good understanding of the stakeholder environment.'

Simon Hackett, deputy managing director at Pegasus said the programme was to focus on Qutenza as a 'topical treatment for patients living with this painful and difficult-to-treat condition. Working on such a significant European programme is a great opportunity.'

This is the first time Pegasus has worked with Astellas.

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

Judge tells Max Clifford trial jury majority verdicts will be accepted

Judge tells Max Clifford trial jury majority verdicts will be accepted

The jury in the trial of celebrity publicist Max Clifford has been told by the judge that he will accept majority verdicts after five days of deliberations on 11 charges of indecent assault.

Labour "fooling themselves" over plans to combat attacks on Miliband

Labour "fooling themselves" over plans to combat attacks on Miliband

Conservative-leaning public affairs experts have questioned the value of Labour's adoption of US-style campaigning tactics in the wake of the opposition hiring election strategist David Axelrod.

PLMR appoints Professor Tim Morris as non-executive director

The vet who helped establish the British Horseracing Authority's anti-doping and animal welfare programme has joined PLMR as a non-executive director.